Arcturus Therapeutics Holdings Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARCT research report →
Companyarcturusrx.com
Arcturus Therapeutics Holdings Inc. , an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
- CEO
- Joseph E. Payne
- IPO
- 2013
- Employees
- 174
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $193.70M
- P/E
- -2.46
- P/S
- 4.27
- P/B
- 1.01
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.18%
- Op Margin
- -196.72%
- Net Margin
- -173.47%
- ROE
- -36.55%
- ROIC
- -42.27%
Growth & Income
- Revenue
- $67.22M · -51.43%
- Net Income
- $-65,783,000 · 18.73%
- EPS
- $-2.40 · 20.00%
- Op Income
- $-74,955,000
- FCF YoY
- -22.98%
Performance & Tape
- 52W High
- $24.17
- 52W Low
- $5.85
- 50D MA
- $7.93
- 200D MA
- $10.67
- Beta
- 2.42
- Avg Volume
- 567.83K
Get TickerSpark's AI analysis on ARCT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | MULROY DENNIS | other | 100,000 |
| May 1, 26 | MULROY DENNIS | other | 0 |
| Dec 17, 25 | Roberts Joseph | other | 10,000 |
| Dec 17, 25 | Chivukula Pad | other | 54,000 |
| Dec 17, 25 | Payne Joseph E | other | 175,000 |
| Dec 17, 25 | Kurata Lance | other | 54,000 |
| Dec 12, 25 | Roberts Joseph | other | 0 |
| Dec 12, 25 | Roberts Joseph | other | 0 |
| Dec 12, 25 | Roberts Joseph | other | 7,500 |
| Dec 12, 25 | Roberts Joseph | other | 5,000 |
Our ARCT Coverage
We haven't published any research on ARCT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARCT Report →